3,160 Shares in Danaher Co. (NYSE:DHR) Bought by Postrock Partners LLC

Postrock Partners LLC acquired a new stake in Danaher Co. (NYSE:DHR) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,160 shares of the conglomerate’s stock, valued at approximately $725,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. FMR LLC lifted its position in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Danaher by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after purchasing an additional 441,012 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after purchasing an additional 148,251 shares in the last quarter. Fisher Asset Management LLC increased its stake in Danaher by 0.6% during the 4th quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock worth $1,051,097,000 after buying an additional 26,305 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Danaher by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate’s stock worth $933,524,000 after buying an additional 135,047 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 11.10% of the company’s stock.

Danaher Stock Down 0.5 %

DHR opened at $203.96 on Friday. The firm’s fifty day moving average price is $220.55 and its two-hundred day moving average price is $241.22. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The company has a market capitalization of $145.77 billion, a P/E ratio of 38.63, a P/E/G ratio of 2.66 and a beta of 0.82.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the previous year, the firm earned $2.09 earnings per share. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a yield of 0.63%. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s payout ratio is currently 24.24%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of analyst reports. The Goldman Sachs Group set a $250.00 target price on Danaher in a research report on Wednesday, January 15th. Robert W. Baird lowered their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Jefferies Financial Group decreased their price objective on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Barclays lowered their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Finally, JPMorgan Chase & Co. reduced their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, January 28th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.